Search | IOVS | ARVO Journals

Showing 1 – 20 of 31

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract July 2018

Static and dynamic assessment of fixation stability in Stargardt disease

Etienne M Schonbach; Artur V Cideciyan; Mohamed A Ibrahim; Rupert Wolfgang Strauss; David G Birch; Janet S Sunness; Srinivas R. Sadda; Hendrik P Scholl

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):788. doi:

ARVO Annual Meeting Abstract July 2018

Progression of Stargardt disease as measured by spectral-domain optical coherence tomography (SD-OCT) in the ProgStar Study

Rupert Wolfgang Strauss; Xiangrong Kong; Beatriz E Munoz; Sheila K West; Michael S Ip; Alexander Ho; Anamika Jha; Paul S Bernstein; David G Birch; Artur V Cideciyan; Michel Michaelides; José-Alain Sahel; Janet S Sunness; Elias I Traboulsi; Eberhart Zrenner; Hendrik P Scholl

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):1568. doi:

ARVO Annual Meeting Abstract July 2018

Reproducibility of a Modified Dual Grading Model Applied to Fundus Autofluorescence Measurements in Macular Atrophy Secondary to Stargardt Disease

Cynthia S. Chan; Alexander Ho; Dennis Jenkins; Sean Pitetta; Manfred Li; Jennifer Tassy; Rupert Wolfgang Strauss; Hendrik P Scholl; Srinivas R. Sadda; Michael S Ip

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):3143. doi:

ARVO Annual Meeting Abstract June 2017

Progression of Atrophic Lesions Determined by Fundus Autofluorescence: The Natural History of the Progression of Atrophy secondary to Stargardt Disease (ProgStar) Study

Rupert Wolfgang Strauss; Xiangrong Kong; Alex Ho; Anamika Jha; Michel Michaelides; Artur V Cideciyan; Jose Alain Sahel; David G Birch; Amir H Hariri; Srinivas R Sadda; Sheila West; Hendrik P Scholl

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):2013. doi:

ARVO Annual Meeting Abstract June 2017

Month 18 changes in microperimetric mean sensitivity, fixation location, and fixation stability in Stargardt disease: The ProgStar Study

Etienne Schonbach; Xiangrong Kong; Mohamed A Ibrahim; Rupert Wolfgang Strauss; David G Birch; Artur V Cideciyan; Muneeswar Gupta Nittala; Janet S Sunness; Eberhart Zrenner; Srinivas R Sadda; Sheila West; Hendrik P Scholl

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):4635. doi:

ARVO Annual Meeting Abstract June 2017

Changes in choroidal vasculature predict visual outcomes in Stargardt disease

Alexander Ho; Siva Balasubramanian; Anamika Jha; Beatriz Munoz; Rupert Wolfgang Strauss; Michael S Ip; Srinivas R Sadda; Hendrik P Scholl

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):4637. doi:

ARVO Annual Meeting Abstract June 2017

Progression of Stargardt disease as measured by spectral-domain optical coherence tomography (SD-OCT) in the ProgStar Study

Mohamed A Ibrahim; Yulia Wolfson; Beatriz Munoz; Rupert Wolfgang Strauss; Sheila West; Swetha Velaga; Nizar Saleh Abdelfattah; Jianyan Huang; Srinivas R Sadda; David G Birch; Eberhart Zrenner; Hendrik P Scholl

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):4640. doi:

ARVO Annual Meeting Abstract June 2017

Natural progression of scotopic and photopic macular function loss in patients with Stargardt disease: The SMART Study.

Millena Bittencourt; Mohamed A Ibrahim; Xiangrong Kong; Rupert Wolfgang Strauss; Ann-Margret Ervin; Alexander Ho; Muneeswar Gupta Nittala; Isabelle S Audo; David G Birch; Hendrik P Scholl

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):3281. doi:

ARVO Annual Meeting Abstract June 2017

Genetic characteristics of an international large cohort with Stargardt disease: The ProgStar study

Kaoru Fujinami; Rupert Wolfgang Strauss; John Chiang; Isabelle S Audo; Paul S Bernstein; David G Birch; Samuel G Jacobson; Brian C Mansfield; Meghan J Marino; Jose Alain Sahel; Saddek Mohand-Said; Janet S Sunness; Elias I Traboulsi; Eberhart Zrenner; Michel Michaelides; Hendrik P Scholl

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):4638. doi:

ARVO Annual Meeting Abstract June 2017

Visual acuity loss during two years in Stargardt Disease: The ProgStar Study

Xiangrong Kong; Rupert Wolfgang Strauss; Beatriz Munoz; Ann-Margret Ervin; Artur V Cideciyan; Michel Michaelides; Mohamed Ahmed; Janet Cheetham; Sheila West; Hendrik P Scholl

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):4647. doi:

ARVO Annual Meeting Abstract September 2016

Impact of segmentation density on spectral domain optical coherence tomography (SD-OCT) assessments in Stargardt disease.

Anamika Jha; Alexander Ho; Muneeswar gupta Nittala; Rupert Wolfgang Strauss; Hendrik P Scholl; Srinivas R Sadda

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):2691. doi:

ARVO Annual Meeting Abstract September 2016

Six-month-change in microperimetric mean sensitivity, fixation location and fixation stability in Stargardt disease: The prospective ProgStar study

Shazia Khan; Xiangrong Kong; Rupert Wolfgang Strauss; Mohamed A Ibrahim; Etienne M. Schonbach; Saddek Mohand-Said; Michel Michaelides; David G Birch; Janet S Sunness; Srinivas R Sadda; Hendrik P Scholl

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12) doi:

ARVO Annual Meeting Abstract September 2016

Progression of atrophic lesions prospectively determined by fundus autofluorescence: the natural history of the progression of atrophy secondary to Stargardt disease (ProgStar) study

Rupert Wolfgang Strauss; Xiangrong Kong; Anamika Jha; Paul S Bernstein; Michel Michaelides; Jose Sahel; Elias I Traboulsi; Eberhart Zrenner; Sheila K West; Srinivas R Sadda; Hendrik P Scholl

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12) doi:

ARVO Annual Meeting Abstract September 2016

Visual acuity loss during one year in Stargardt Disease: ProgStar Prospective Study

Xiangrong Kong; Rupert Wolfgang Strauss; Ann-Margret Ervin; Paul S Bernstein; Artur V Cideciyan; Janet S Sunness; Elias I Traboulsi; Beatriz E Munoz; Mohamed Ahmed; Sheila K West; Hendrik P Scholl

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12) doi:

ARVO Annual Meeting Abstract September 2016

Repeatability of contrast testing and the comparison of contrast sensitivity between normal and glaucomatous eyes

Simrat K Sodhi; Saghar Bagheri; Yulia Wolfson; Pradeep Y Ramulu; Pujan Dave; Luis A Lesmes; Emma McDonnell; Rupert Wolfgang Strauss; David S Friedman; Hendrik P Scholl

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):617. doi:

ARVO Annual Meeting Abstract September 2016

Results from spectral-domain optical coherence tomography (SD-OCT) at baseline compared with normative data: The Natural History of the Progression of Atrophy Secondary to Stargardt Disease (ProgStar) Study

Alexander Ho; Beatriz E Munoz; Rupert Wolfgang Strauss; Anamika Jha; Ngoc Lam; Zhihong Hu; David G Birch; Eberhart Zrenner; Sheila K West; Srinivas R Sadda; Hendrik P Scholl

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):2697. doi:

ARVO Annual Meeting Abstract September 2016

Associations between fundus autofluorescence and spectral-domain optical coherence tomography in Stargardt disease at baseline of the prospective ProgStar study.

Yulia Wolfson; Beatriz E Munoz; Rupert Wolfgang Strauss; Alexander Ho; Anamika Jha; Elias I Traboulsi; Artur V Cideciyan; Michel Michaelides; Srinivas R Sadda; Sheila K West; Hendrik P Scholl

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12) doi:

ARVO Annual Meeting Abstract September 2016

Cross-sectional evaluation of microperimetric fixation location and stability in Stargardt disease in the ProgStar study

Etienne M. Schonbach; Mohamed A Ibrahim; Rupert Wolfgang Strauss; Xiangrong Kong; Alexander Ho; Paul S Bernstein; Janet S Sunness; Eberhart Zrenner; Srinivas R Sadda; Sheila K West; Hendrik P Scholl

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):2694. doi:

ARVO Annual Meeting Abstract September 2016

The natural history of the progression of atrophy secondary to Stargardt disease type 4 (Progstar-4 Study): Baseline demographics and ocular characteristics of patients with PROM-1 related retinal dystrophy.

Syed Mahmood Ali Shah; Mohamed Ahmed; Nadia Junaid; Saghar Bagheri; Beatriz E Munoz; Rupert Wolfgang Strauss; Etienne M. Schonbach; Michel Michaelides; Ann-Margret Ervin; Hendrik P Scholl

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):2695. doi:

ARVO Annual Meeting Abstract September 2016

Scotopic and photopic macular functions as assessed with microperimetry (MP1) in patients with Stargardt disease type 1 – The SMART Study

Mohamed A Ibrahim; Rupert Wolfgang Strauss; Xiangrong Kong; Ann-Margret Ervin; Alexander Ho; Janet S Sunness; Isabelle S Audo; David G Birch; Srinivas R Sadda; Millena G Bittencourt; Hendrik P Scholl

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):2696. doi:

1 2

Next 20 Results »

NARROW

Content Type

Journal

Article Type

Specify Date Range

Static and dynamic assessment of fixation stability in Stargardt disease

Progression of Stargardt disease as measured by spectral-domain optical coherence tomography (SD-OCT) in the ProgStar Study

Reproducibility of a Modified Dual Grading Model Applied to Fundus Autofluorescence Measurements in Macular Atrophy Secondary to Stargardt Disease

Progression of Atrophic Lesions Determined by Fundus Autofluorescence: The Natural History of the Progression of Atrophy secondary to Stargardt Disease (ProgStar) Study

Month 18 changes in microperimetric mean sensitivity, fixation location, and fixation stability in Stargardt disease: The ProgStar Study

Changes in choroidal vasculature predict visual outcomes in Stargardt disease

Progression of Stargardt disease as measured by spectral-domain optical coherence tomography (SD-OCT) in the ProgStar Study

Natural progression of scotopic and photopic macular function loss in patients with Stargardt disease: The SMART Study.

Genetic characteristics of an international large cohort with Stargardt disease: The ProgStar study

Visual acuity loss during two years in Stargardt Disease: The ProgStar Study

Impact of segmentation density on spectral domain optical coherence tomography (SD-OCT) assessments in Stargardt disease.

Six-month-change in microperimetric mean sensitivity, fixation location and fixation stability in Stargardt disease: The prospective ProgStar study

Progression of atrophic lesions prospectively determined by fundus autofluorescence: the natural history of the progression of atrophy secondary to Stargardt disease (ProgStar) study

Visual acuity loss during one year in Stargardt Disease: ProgStar Prospective Study

Repeatability of contrast testing and the comparison of contrast sensitivity between normal and glaucomatous eyes

Results from spectral-domain optical coherence tomography (SD-OCT) at baseline compared with normative data: The Natural History of the Progression of Atrophy Secondary to Stargardt Disease (ProgStar) Study

Associations between fundus autofluorescence and spectral-domain optical coherence tomography in Stargardt disease at baseline of the prospective ProgStar study.

Cross-sectional evaluation of microperimetric fixation location and stability in Stargardt disease in the ProgStar study

The natural history of the progression of atrophy secondary to Stargardt disease type 4 (Progstar-4 Study): Baseline demographics and ocular characteristics of patients with PROM-1 related retinal dystrophy.

Scotopic and photopic macular functions as assessed with microperimetry (MP1) in patients with Stargardt disease type 1 – The SMART Study

To View More...

You must be signed into an individual account to use this feature.